The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)
Part of paid clinical trials in Cities in Alabama, Alabama.
- Sponsor
- AstraZeneca
- Study ID
- NCT00076076
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Roflumilast — DRUG
Study Details
The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and asthma symptoms.
Key Dates
- Start date
- Dec 31, 2003
- Status verified
- Sep 2016
- Completion
- Jun 30, 2005
Study Design
- Enrollment
- 822 participants
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Primary Outcome Measure
change in lung function.
Locations (39)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| ALTANA Pharma | Cities in Alabama | Alabama | - | - |
| ALTANA Pharma | Cities in Arizona | Arizona | - | - |
| ALTANA Pharma | Cities in Arkansas | Arkansas | - | - |
| ALTANA Pharma | Cities in California | California | - | - |
| ALTANA Pharma | Cities in Colorado | Colorado | - | - |
| ALTANA Pharma | Cities in Connecticut | Connecticut | - | - |
| ALTANA Pharma | Cities in Delaware | Delaware | - | - |
| ALTANA Pharma | Cities in Florida | Florida | - | - |
| ALTANA Pharma | Cities in Georgia | Georgia | - | - |
| ALTANA Pharma | Cities in Illinois | Illinois | - | - |
| ALTANA Pharma | Cities in Indiana | Indiana | - | - |
| ALTANA Pharma | Cities in Kansas | Kansas | - | - |
| ALTANA Pharma | Cities in Kentucky | Kentucky | - | - |
| ALTANA Pharma | Cities in Louisiana | Louisiana | - | - |
| ALTANA Pharma | Cities in Maine | Maine | - | - |
| ALTANA Pharma | Cities in Maryland | Maryland | - | - |
| ALTANA Pharma | Cities in Massachusetts | Massachusetts | - | - |
| ALTANA Pharma | Cities in Michigan | Michigan | - | - |
| ALTANA Pharma | Cities in Minnesota | Minnesota | - | - |
| ALTANA Pharma | Cities in Missouri | Missouri | - | - |
| ALTANA Pharma | Cities in Montana | Montana | - | - |
| ALTANA Pharma | Cities in Nebraska | Nebraska | - | - |
| ALTANA Pharma | Cities in Nevada | Nevada | - | - |
| ALTANA Pharma | Cities in New Jersey | New Jersey | - | - |
| ALTANA Pharma | Cities in New York | New York | - | - |
| ALTANA Pharma | Cities in North Carolina | North Carolina | - | - |
| ALTANA Pharma | Cities in Ohio | Ohio | - | - |
| ALTANA Pharma | Cities in Oklahoma | Oklahoma | - | - |
| ALTANA Pharma | Cities in Oregon | Oregon | - | - |
| ALTANA Pharma | Cities in Pennsylvania | Pennsylvania | - | - |
| ALTANA Pharma | Cities in Rhode Island | Rhode Island | - | - |
| ALTANA Pharma | Cities in South Carolina | South Carolina | - | - |
| ALTANA Pharma | Cities in Tennessee | Tennessee | - | - |
| ALTANA Pharma | Cities in Texas | Texas | - | - |
| ALTANA Pharma | Cities in Utah | Utah | - | - |
| ALTANA Pharma | Cities in Vermont | Vermont | - | - |
| ALTANA Pharma | Cities in Virginia | Virginia | - | - |
| ALTANA Pharma | Cities in Washington | Washington | - | - |
| ALTANA Pharma | Cities in West Virginia | West Virginia | - | - |
Find similar trials in Cities in Alabama, AL
By condition
By specialty
Related Studies
- Role of Genetic Factors in the Development of Lung DiseaseRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Personalized Environment and Genes StudyRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent AsthmaRecruiting · Gelb, Arthur F., M.D. · Lakewood, California
- Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway InflammationPHASE1 · Recruiting · Benjamin Medoff · Boston, Massachusetts